These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 33594427)

  • 1. Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study).
    Tomita Y; Kimura G; Fukasawa S; Numakura K; Sugiyama Y; Yamana K; Naito S; Kabu K; Tajima Y; Oya M
    Jpn J Clin Oncol; 2021 May; 51(6):966-975. PubMed ID: 33594427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
    Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
    Tomita Y; Kimura G; Fukasawa S; Numakura K; Sugiyama Y; Yamana K; Naito S; Kaneko H; Tajima Y; Oya M
    Jpn J Clin Oncol; 2021 Nov; 51(11):1656-1664. PubMed ID: 34350454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
    Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.
    Iinuma K; Kameyama K; Kawada K; Fujimoto S; Takagi K; Nagai S; Ito H; Ishida T; Kawase M; Kawase K; Nakai C; Kato D; Takai M; Nakane K; Koie T
    Curr Oncol; 2021 Apr; 28(2):1402-1411. PubMed ID: 33916792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.
    George DJ; Spigel DR; Gordan LN; Kochuparambil ST; Molina AM; Yorio J; Rezazadeh Kalebasty A; McKean H; Tchekmedyian N; Tykodi SS; Zhang J; Askelson M; Johansen JL; Hutson TE
    BMJ Open; 2022 Sep; 12(9):e058396. PubMed ID: 36104138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
    Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
    ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
    Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
    Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
    Motzer RJ; McDermott DF; Escudier B; Burotto M; Choueiri TK; Hammers HJ; Barthélémy P; Plimack ER; Porta C; George S; Powles T; Donskov F; Gurney H; Kollmannsberger CK; Grimm MO; Barrios C; Tomita Y; Castellano D; Grünwald V; Rini BI; McHenry MB; Lee CW; McCarthy J; Ejzykowicz F; Tannir NM
    Cancer; 2022 Jun; 128(11):2085-2097. PubMed ID: 35383908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
    Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI
    Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
    Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
    Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
    Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
    Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
    Alhalabi O; Hasanov E; Wilson NR; Araujo J; Wang J; Campbell MT; Goswami S; Shah AY; Gao J; Msaouel P; Tannir NM
    Int J Cancer; 2021 Jul; 149(2):387-393. PubMed ID: 33739450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
    Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Leung D; Saggi SS; Lee CW; McHenry MB; Motzer RJ
    Eur Urol; 2022 Mar; 81(3):266-271. PubMed ID: 34750035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
    Emamekhoo H; Olsen MR; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Rezazadeh Kalebasty A; George DJ; Hutson TE; Arrowsmith ER; Zhang J; Zoco J; Johansen JL; Leung DK; Tykodi SS
    Cancer; 2022 Mar; 128(5):966-974. PubMed ID: 34784056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
    Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
    Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.
    Monteiro FSM; Soares A; Debiasi M; Schutz FA; Maluf FC; Bastos DA; Sasse A; Cauduro CGS; Mendes GO; Ziegelmann PK; Fay AP
    Clin Genitourin Cancer; 2020 Aug; 18(4):244-251.e4. PubMed ID: 32303427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors.
    Kato R; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109443. PubMed ID: 36403521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.